Antiproliferative Effect of Lanreotide in Low Grade Neuroendocrine Neoplasms: Two Case Reports Abstract #1085

Introduction: Somatostatin analogs are used for control of symptoms due to hormonal hypersecretion by neuroendocrine neoplasms (NEN). Their antiproliferative effect only recently became evident. Data on pancreatic NEN (pNEN) are limited.
Aim(s): We present patients with pNEN that received Lanreotide.
Materials and methods: 2 case reports
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Michael Vaslamatzis
Keywords: NEN, lanreotide

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2124 A Case Report of a Malignant Insulinoma
Introduction: Despite rare (1-2% of pancreatic tumors/PT), insulinomas are the most common functional pNET. The diagnosis is established by demonstrating inappropriately high serum insulin levels during a spontaneous or induced episode of hypoglycemia.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Theodoros Tegos
Keywords: malignant, insulinoma
#1846 Metachronous Pancreatic Neuroendocrine Tumors. An Unusual Interesting Case Report
Introduction: Literature surveillance state that in multiple endocrine neoplasia (MEN) disease, frequently occur, synchronous or metachronous neuroendocrine tumors (NETs) but in non-MEN patients are extremely rare.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: DR Nektarios Alevizopoulos
Keywords: pancreatic
#2300 Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)
Introduction: Lanreotide AG currently is used as standard initial therapy in NETG1 & G2 pancreatic NEN with Ki-67<10%.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Jaroslaw Ćwikła
#1915 Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro
Introduction: SSA represent the standard of care for controlling symptoms of patients with functional GEP-NEN and have anti-proliferative effects. Molecular targeted therapies (MTT) against angiogenesis resulted in an increased PFS, however, due to primary and acquired resistance to MTT, the impact on OS remains unclear. One of the most pivotal questions, whether combining SSA with novel MTT will result in enhanced anti-proliferative activity compared to monotherapy treatment, are lacking.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Sebastian Krug
#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience
Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Julian Gertner
Keywords: homecare